Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.35 |
| ▸ | IRAK2 | O43187 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138979 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL862083 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL1699971 | 0.98 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL15227231 | 0.98 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL16593368 | 0.98 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL1699970 | 0.98 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL15134619 | 0.88 | HRH3 (0.44) | SMN1; SMN2HRH3 | |
| SCHEMBL3168997 | 0.87 | — | — | |
| SCHEMBL26112782 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL26112778 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12514859-B2 | Pyrazole pyrimidine derivative and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2026-01-06 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12378250-B2 | Tricyclic compound as IRAK4 inhibitor | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-08-05 | — | — | US | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250145625-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-05-08 | — | — | US | disclosed |
| WO-2025076441-A1 | COMPOUNDS OF GCN2 MODULATORS | Alesta Therapeutics BV (NL) | 2025-04-10 | — | — | WO | disclosed |
| US-20250049793-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-02-13 | — | — | US | disclosed |
| EP-3885348-B1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | KOREA RES INST CHEMICAL TECH (KR) | 2025-02-12 | — | — | EP | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | 2005-01-20 | — | — | US | disclosed |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004106493-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| EP-1465889-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | AnorMED Inc. (CA) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004076454-A1 | DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-09-10 | — | — | WO | disclosed |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2004-01-29 | — | — | US | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
| WO-2003055876-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885L3MBTL3 1788/4885L3MBTL1 1394/4885 |
| US-20250145625-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | DPYD, TP53, WASHC5 | SMN1; SMN2 3352/4885L3MBTL3 4871/4885L3MBTL1 4872/4885 |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | QDPR, DHPS, DRD5 | SMN1; SMN2 4582/4885L3MBTL3 4854/4885L3MBTL1 4487/4885 |
| US-12378250-B2 | Tricyclic compound as IRAK4 inhibitor | IRAK4, IRAK1, IRAK2 | SMN1; SMN2 2401/4885L3MBTL3 3661/4885L3MBTL1 1925/4885 |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | SMN1; SMN2 3624/4885L3MBTL3 1310/4885L3MBTL1 1929/4885 |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | QDPR, DHPS, DHFR | SMN1; SMN2 1711/4885L3MBTL3 1941/4885L3MBTL1 1277/4885 |
| US-20250049793-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | IRAK1, IRAK2, IRAK3 | SMN1; SMN2 2496/4885L3MBTL3 4219/4885L3MBTL1 2987/4885 |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | QDPR, DHPS, DHODH | SMN1; SMN2 4436/4885L3MBTL3 3917/4885L3MBTL1 3166/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | SMN1; SMN2 3901/4885L3MBTL3 4712/4885L3MBTL1 4535/4885 |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | SMN1; SMN2 3624/4885L3MBTL3 1310/4885L3MBTL1 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.